Celsion says ThermoDox, ultrasound combo delays tumor growth

By Elaine Rigoli

Tampa, Fla., Aug. 31 - Celsion Corp., the Columbia, Md., biotechnology company, is set to release the results from a study that treated tumors in mice with either ThermoDox combined with pulsed high intensity focused ultrasound (HIFU) or Doxil combined with pulsed HIFU.

The company said early results suggest that ThermoDox (heat-sensitive liposomal doxorubicin) administered in combination with pulsed HIFU increased doxorubicin concentrations in the tumors and prolonged the delay in tumor growth in comparison to the combination of HIFU with Doxil, a non-heat sensitive liposomal formulation of doxorubicin.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.